RhumbLine Advisers’s Alto Neuroscience ANRO Stock Holding History

RhumbLine Advisers’s Portfolio ANRO Stock Details ANRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-27,127	Closed	-$58.6K	–	4280
2025 Q1	$58.6K	Buy	27,127 +1,571	+6%	+$5.62K	﹤0.01%	3536
2024 Q4	$108K	Buy	25,556 +5,008	+24%	+$31.3K	﹤0.01%	3458
2024 Q3	$235K	Buy	20,548 +10,009	+95%	+$122K	﹤0.01%	3155
2024 Q2	$113K	Buy	+10,539	New	+$137K	﹤0.01%	3487

Other funds holding ANRO

AWG

Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

7IH

72 Investment Holdings Stamford, Connecticut $49.6M AUM 684.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

RhumbLine Advisers's ANRO Position: Q2 2025 in Review

RhumbLine Advisers sold out of Alto Neuroscience (ANRO) in Q2 2025, closing a stake of 27,127 shares — an estimated $58.6K sold.

RhumbLine Advisers first reported a position in ANRO in Q2 2024 and held it in 4 quarters. The position peaked at $235K in Q3 2024. 80 funds tracked by Wall St. Rank hold ANRO as of Q2 2025.

RhumbLine Advisers reported no remaining Alto Neuroscience position as of Q2 2025 after selling out during the quarter.
RhumbLine Advisers sold 27,127 Alto Neuroscience shares in Q2 2025, an estimated $58.6K.
RhumbLine Advisers first reported a position in Alto Neuroscience in Q2 2024 and held it in 4 quarters.
RhumbLine Advisers's Alto Neuroscience position peaked at $235K in Q3 2024.
80 funds tracked by Wall St. Rank held Alto Neuroscience as of Q2 2025.

Based on RhumbLine Advisers's 13F filing for Q2 2025, filed 12 Aug 2025.